Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01)
Cyclobenzaprine Hydrochloride
Product Images NDC 71550-101
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Cyclobenzaprine Hydrochloride (NDC 71550-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Virtue Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Table 1 (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)
This is a table summarizing the side effects of Cyclobenzaprine HCI tablets in 5mg and 10mg doses, as well as the placebo. The side effects listed include drowsiness, dry mouth, fatigue, and headache. The table includes the number of participants in each group (N) and the percentage of participants reporting each side effect.*
Table 2 (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)
This text provides information on the side effects of Cyclobenzaprine HClI Tablets, 10 mg based on clinical studies and a surveillance program. The side effects mentioned in the clinical studies are drowsiness (39%), dry mouth (2%) and dizziness (1%). The surveillance program reports higher rates of side effects with Cyclobenzaprine HCI tablets, including drowsiness (16%), dry mouth (7%), and dizziness (3%).*
Label (F10382 Label)
Cyclobenzaprine hydrochloride tablets, USP, are typically taken at a standard dosage, as instructed by the accompanying product information and prescription. The medication should be stored under controlled temperatures, with the appropriate range listed as 20-25 degrees Celsius or 68-77 degrees Fahrenheit. The packaging labels the product with the NDC code 71550-101.01 and contains 100 tablets.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
